Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778349 | 0.84 | L3MBTL1 (0.57) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL28413664 | 0.84 | GLA (0.56) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL2262931 | 0.84 | L3MBTL1 (0.61) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL9415751 | 0.82 | GLA (0.67) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL14041701 | 0.81 | ATM (0.68) | L3MBTL1LMNAALDH1A1HSD17B10RAB9A | |
| SCHEMBL5451707 | 0.81 | GLA (0.61) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL19574225 | 0.81 | ATM (0.75) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7694058 | 0.80 | GLA (0.65) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL3404224 | 0.80 | L3MBTL1 (0.63) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL423999 | 0.79 | L3MBTL1 (0.61) | L3MBTL1TSHRPOLBGLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2014071109-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014004470-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-8067454-B2 | Thio-substituted Anthra [1, 2-d] imidazole- 6, 11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-11-29 | — | — | US | disclosed |
| US-20110207727-A1 | Thio-subsituted Anthra [1, 2-d] imidazole- 6, 11-dione Dervatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
| WO-2011048936-A1 | AMINOTHIAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207727-A1 | Thio-subsituted Anthra [1, 2-d] imidazole- 6, 11-dione Dervatives, Preparation Method and application thereof | TERT, ACIN1, TERF2 | L3MBTL1 3662/4885TSHR 790/4885POLB 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.